Search Result

Results for "

anti-EGFR

" in MedChemExpress (MCE) Product Catalog:

By Targets:	EGFR (11) ADC Cytotoxin (1) Antibody-Drug Conjugates (ADCs) (1) Drug Metabolite (1) Fluorescent Dye (2)
By Research Areas:	Cancer (14)

Inhibitors & Agonists

Inhibitory Antibodies

Targets Recommended: EGFR

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P99041A

*Panitumumab (anti-EGFR)*	EGFR	Cancer
Panitumumab (anti-EGFR) is a fully human IgG2 anti-EGFR monoclonal antibody with anti-tumor activity. Panitumumab (anti-EGFR) inhibits tumor cell proliferation, survival and angiogenesis. Panitumumab (anti-EGFR) can be used in the research of cancers, such as colon cancer .

HY-P9969

Matuzumab

EMD 72000
EGFR Cancer

Matuzumab (EMD 72000) is a humanized anti-EGFR monoclonal antibody that blocks EGFR activation and downstream signaling, inhibits tumor growth .

Matuzumab EMD 72000	EGFR	Cancer
Matuzumab (EMD 72000) is a humanized anti-EGFR monoclonal antibody that blocks EGFR activation and downstream signaling, inhibits tumor growth .

HY-D1464

CH1055 1 Publications Verification	Fluorescent Dye	Cancer
CH1055 is a NIR-II fluorophore based on a synthetic 970-Da organic molecule. CH1055 is a rapidly excreted dye (∼90% excreted through the kidneys within 24 h). CH1055 also allows targeted molecular imaging of tumors in vivo when conjugated with anti-EGFR Affibody .

HY-D1464A

CH1055 triethylamine 1 Publications Verification	Fluorescent Dye	Cancer
CH1055 triethylamine is a NIR-II fluorophore based on a synthetic 970-Da organic molecule. CH1055 triethylamine is a rapidly excreted dye (∼90% excreted through the kidneys within 24 h). CH1055 triethylamine also allows targeted molecular imaging of tumors in vivo when conjugated with anti-EGFR Affibody .

HY-P99295

Imgatuzumab RG 7160; RO 5083945; anti-EGFR Recombinant antibody	EGFR	Cancer
Imgatuzumab (RG 7160) is a humanized monoclonal antibody against the *EGFR*. Imgatuzumab acts as an immunomodulator. Imgatuzumab can be used in research of cancer .

HY-P99041

Panitumumab 1 Publications Verification ABX-EGF	EGFR	Cancer
Panitumumab (ABX-EGF) is a fully human IgG2 anti-EGFR monoclonal antibody with anti-tumor activity. Panitumumab inhibits tumor cell proliferation, survival and angiogenesis. Panitumumab can be used in the research of cancers, such as colon cancer .

HY-P99684

Laprituximab

J2898A
EGFR Cancer

Laprituximab (J2898A) is a humanized IgG1 anti-EGFR antibody that can be used for the synthesis of ADC IMGN289 .

Laprituximab J2898A	EGFR	Cancer
Laprituximab (J2898A) is a humanized IgG1 anti-EGFR antibody that can be used for the synthesis of ADC IMGN289 .

HY-P99296

Intetumumab CNTO 95; anti-Human CD51 Recombinant antibody	EGFR	Cancer
Intetumumab (CNTO 95) is a potent anti-EGFR monoclonal antibody that is glycoengineered for enhanced antibody-dependent cellular cytotoxicity (ADCC). Intetumumab can be used in research of cancer .

HY-144880

SC209	ADC Cytotoxin EGFR Drug Metabolite	Cancer
SC209, an ADC cytotoxin extracted from patent WO2021247798, is used in synthesis of anti-EGFR antibody-drug conjugate ADC. SC209 is a metabolite of STRO-002 .

HY-P99715

Losatuxizumab ABT-806	EGFR	Cancer
Losatuxizumab (ABT-806) is an anti-EGFR monoclonal antibody. Losatuxizumab binds to EGFR with EC₅₀s of 0.96 nM for EGFR wild-type, 0.09 nM for EGFR ^C271A,C283A, 0.12 nM for EGFRvIII, 0.66 nM for EGFR1-501. Losatuxizumab can be used for research of EGFR-expressing cancers .

HY-P99676

Izalontamab SI-B001	EGFR	Cancer
Izalontamab (SI-B001) is a bispecific *anti-EGFR/HER3* monoclonal antibody with high selectivity for EGFR/HER3 heterodimer. Izalontamab can be used for the research of cancer .

HY-P99849

Depatuxizumab ABT-806	EGFR	Cancer
Depatuxizumab is a brain-penetrant and humanized tumor-specific anti EGFR monoclonal antibody. Depatuxizumab inhibits the growth of xenograft models of mutant EGFRvIII and wild-type EGFR. Depatuxizumab can be used for research on cancer .

HY-156712

Depatuxizumab MMAE	Antibody-Drug Conjugates (ADCs)	Cancer
Depatuxizumab MMAE is an antibody-drug conjugate (ADC) comprising an anti EGFR monoclonal antibody (Depatuxizumab) and the cytotoxic agent Monomethyl auristatin E (MMAE). Depatuxizumab inhibits the growth of xenograft models of mutant EGFRvIII and wild-type EGFR .

HY-P99406

Petosemtamab MCLA 158	EGFR	Cancer
Petosemtamab (MCLA 158) is an anti- EGFR (K_d: 0.22 nM) and anti-LGR5 (K_d: 0.86 nM) monoclonal antibody (mAb). Petosemtamab leads to EGFR signaling blockade and receptor degradation in LGR5+ cancer cells. Petosemtamab can be used in the research of solid tumors, such as head and neck squamous cell carcinoma (HNSCC), metastatic colorectal cancer (CRC) .

Cat. No.	Product Name	Target	Research Area

HY-P99041A

*Panitumumab (anti-EGFR)*	EGFR	Cancer
Panitumumab (anti-EGFR) is a fully human IgG2 anti-EGFR monoclonal antibody with anti-tumor activity. Panitumumab (anti-EGFR) inhibits tumor cell proliferation, survival and angiogenesis. Panitumumab (anti-EGFR) can be used in the research of cancers, such as colon cancer .

HY-P9969

Matuzumab

EMD 72000
EGFR Cancer

Matuzumab (EMD 72000) is a humanized anti-EGFR monoclonal antibody that blocks EGFR activation and downstream signaling, inhibits tumor growth .

Matuzumab EMD 72000	EGFR	Cancer
Matuzumab (EMD 72000) is a humanized anti-EGFR monoclonal antibody that blocks EGFR activation and downstream signaling, inhibits tumor growth .

HY-P99041

Panitumumab 1 Publications Verification ABX-EGF	EGFR	Cancer
Panitumumab (ABX-EGF) is a fully human IgG2 anti-EGFR monoclonal antibody with anti-tumor activity. Panitumumab inhibits tumor cell proliferation, survival and angiogenesis. Panitumumab can be used in the research of cancers, such as colon cancer .

HY-P99684

Laprituximab

J2898A
EGFR Cancer

Laprituximab (J2898A) is a humanized IgG1 anti-EGFR antibody that can be used for the synthesis of ADC IMGN289 .

Laprituximab J2898A	EGFR	Cancer
Laprituximab (J2898A) is a humanized IgG1 anti-EGFR antibody that can be used for the synthesis of ADC IMGN289 .

HY-P99295

Imgatuzumab RG 7160; RO 5083945; anti-EGFR Recombinant antibody	EGFR	Cancer
Imgatuzumab (RG 7160) is a humanized monoclonal antibody against the *EGFR*. Imgatuzumab acts as an immunomodulator. Imgatuzumab can be used in research of cancer .

HY-P99296

Intetumumab CNTO 95; anti-Human CD51 Recombinant antibody	EGFR	Cancer
Intetumumab (CNTO 95) is a potent anti-EGFR monoclonal antibody that is glycoengineered for enhanced antibody-dependent cellular cytotoxicity (ADCC). Intetumumab can be used in research of cancer .

HY-P99715

Losatuxizumab ABT-806	EGFR	Cancer
Losatuxizumab (ABT-806) is an anti-EGFR monoclonal antibody. Losatuxizumab binds to EGFR with EC₅₀s of 0.96 nM for EGFR wild-type, 0.09 nM for EGFR ^C271A,C283A, 0.12 nM for EGFRvIII, 0.66 nM for EGFR1-501. Losatuxizumab can be used for research of EGFR-expressing cancers .

HY-P99676

Izalontamab SI-B001	EGFR	Cancer
Izalontamab (SI-B001) is a bispecific *anti-EGFR/HER3* monoclonal antibody with high selectivity for EGFR/HER3 heterodimer. Izalontamab can be used for the research of cancer .

HY-P99849

Depatuxizumab ABT-806	EGFR	Cancer
Depatuxizumab is a brain-penetrant and humanized tumor-specific anti EGFR monoclonal antibody. Depatuxizumab inhibits the growth of xenograft models of mutant EGFRvIII and wild-type EGFR. Depatuxizumab can be used for research on cancer .

HY-P99406

Petosemtamab MCLA 158	EGFR	Cancer
Petosemtamab (MCLA 158) is an anti- EGFR (K_d: 0.22 nM) and anti-LGR5 (K_d: 0.86 nM) monoclonal antibody (mAb). Petosemtamab leads to EGFR signaling blockade and receptor degradation in LGR5+ cancer cells. Petosemtamab can be used in the research of solid tumors, such as head and neck squamous cell carcinoma (HNSCC), metastatic colorectal cancer (CRC) .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.